Table 1.
Monoclonal antibodies currently ongoing phase 2, 3 and 4 trial.
| Donor/ sponsor | Product | Clinical stage | Trial ID | Study |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | REGN10933 + REGN10987 combination therapy (Directed against RBD of S-protein of SARS-CoV-2) | Phase 1/2 | NCT04425629 | 2,014 ambulatory patients with COVID-19 |
| Regeneron Pharmaceuticals | REGN10933 + REGN10987 combination therapy (Directed against RBD of S-protein of SARS-CoV-2) | Phase 1/2 | NCT04426695 | 2,970 adult Hospitalized COVID-19 patients |
| Sorrento Therapeutics, Inc. | COVI-AMG (mAb targeting S-protein epitope, specifically D614G variant) | Phase 1/2 | NCT04584697 | 50 SARS-CoV-2 RNA positive asymptomatic/mild symptomatic participants |
| University of Cologne/ZKS Koln/Boehringer Ingelheim | human monoclonal antibody DZIF-10c | Phase 1/2a | NCT04631666 | 69 SARS-CoV-2 RNA negative and positive individuals |
| Swedish Orphan Biovitrum | Emapalumab (Anti-interferon gamma mAB) or Anakinra (Interleukin-1 Receptor Antagonist) | Phase 2 | NCT04324021 | 54 hospitalized COVID-19 patients with respiratory distress and hyper inflammation |
| Assistance Publique - Hôpitaux de Paris | Tocilizumab (Anti IL-6 mAB) | Phase 2 | NCT04331808 | 228 COVID-19 patients included in CORIMUNDO-19 cohort |
| CytoDyn, Inc. | Leronlimab (CCR-5 receptor inhibitor) | Phase 2 | NCT04347239 | 390 hospitalized severe or critically ill COVID-19 patients |
| Kinevant Sciences GmbH/Roivant Sciences, Inc. | Gimsilumab (mAb against GM-CSF) | Phase 2 | NCT04351243 | 227 with lung injury or ARDS secondary to COVID-19 |
| Maria del Rosario Garcia de Vicuña Pinedo/Instituto de Investigación Sanitaria Hospital Universitario de la Princesa | Sarilumab (human IgG1 mAb that inhibits IL-6 mediated signaling) | Phase 2 | NCT04357808 | 30 patients with moderate-severe COVID-19 infection |
| Implicit Bioscience/University of Washington | IC14(antibody to CD14 pattern recognition receptor) | Phase 2 | NCT04391309 | 300 adult Hospitalized COVID-19 patients |
| Ospedale San Raffaele | Mavrilimumab (mAb against GM-CSF receptor alpha) | Phase 2 | NCT04397497 | 50 participants hospitalized with COVID-19 induced pneumonia |
| CSL Behring | Garadacimab, (Factor XIIa antagonist) | Phase 2 | NCT04409509 | 124 COVID-19 positive severe patients with interstitial pneumonia |
| Hospices Civils de Lyon | Nivolumab (Anti-PD1 antibody) | Phase 2 | NCT04413838 | 120 SARS-CoV-2 positive hospitalized obese individual with risk of severe infection |
| Fibrogen | Pamrevlumab (antibody against connective tissue growth factor) | Phase 2 | NCT04432298 | 130 acute COVID-19 hospitalized patients |
| Johns Hopkins University/ Novartis/ Socar Research SA/ Brigham and Women's Hospital | Crizanlizumab (mAb that reduced inflammation by binding to p-selectin) | Phase 2 | NCT04435184 | 40 SARS-CoV-2 positive hospitalized acute COVID-19 patients |
| Assistance Publique - Hôpitaux de Paris/ Institut National de la Santé Et de la Recherche Médicale, France | Tocilizumab (Anti IL-6 mAB) | Phase 2 | NCT04476979 | 120 COVID-19 patients included in the CORIMUNO-19 cohort |
| Rapa Therapeutics LLC/ Hackensack Meridian Health | RAPA-501-Allo | Phase 2 | NCT04482699 | 88 hospitalized, severe, post-intubation COVID-19 patients |
| National Institute of Allergy and Infectious Diseases (NIAID) | Risankizumab (IL-23 inhibiting mAb) | Phase 2 | NCT04583956 | 200 SARS-CoV-2 positive hospitalized adult patient |
| National Institute of Allergy and Infectious Diseases (NIAID) | Lenzilumab (mAb targeting GM-CSF) | Phase 2 | NCT04583969 | 200 SARS-CoV-2 positive hospitalized adult patients |
| Eli Lilly and Company/AbCellera Biologics Inc./ Shanghai Junshi Bioscience Co., Ltd. | LY3819253 or LY3819253 + LY3832479 (mAB targeting S-protein epitope) | Phase 2 | NCT04634409 | 500 non-hospitalized mild to moderate COVID-19 patients |
| Assistance Publique - Hôpitaux de Paris | Sarilumab (human IgG1 mAb that inhibits IL-6 mediated signaling) | Phase 2/3 | NCT04324073 | 239 COVID-19 patients included in CORIMUNO-19 cohort |
| I-Mab Biopharma Co. Ltd. | TJ003234 (Anti-GM-CSF mAb) | Phase 2/3 | NCT04341116 | 384 severe COVID-19 patients under supportive care |
| Eli Lilly and company/ AbCellera Biologics Inc./Shanghai Junshi Bioscience Co., Ltd. | LY3819253 and LY3832479 (mAb targeting S-protein epitope) | Phase 2/3 | NCT04427501 | 2,450 participants with mild to moderate COVID-19 illness |
| Alexion Pharmaceuticals | Ravulizumab (prevent activation of complement component-5) | Phase 3 | NCT04369469 | 270 hospitalized COVID-19 patients with severe pneumonia, acute lung injury, or ARDS |
| Regeneron Pharmaceuticals | REGN10933 + REGN10987 (mAB targeting S-protein epitope) | Phase 3 | NCT04452318 | 2,000 participants including household contacts of COVID-19 patients |
| Brigham and Women's Hospital | Ravulizumab (mAb targeting C5 complement inhibition) | Phase 3 | NCT04570397 | 32 SARS-CoV-2 positive patients with thrombotic microangiopathy |
| AstraZeneca/QuintilesIMS | AZD7442 (combination of AZD8895 and AZD1061 targeting S-protein of SARS-CoV-2) | Phase 3 | NCT04625725 | 5,000 participants as pre-exposure prophylaxis |
| AstraZeneca/QuintilesIMS | AZD7442(combination of AZD8895 and AZD1061 targeting S-protein of SARS-CoV-2) | Phase 3 | NCT04625972 | 1,125 participants with exposure history within preceding 8 days |
| Hadassah Medical Organization/ Sheba Medical Center/ Wolfson Medical Center | Tocilizumab (Anti IL-6 mAb) | Phase 4 | NCT04377750 | 500 participants with severe COVID-19 disease and suspected hyper-inflammation |
| Cambridge University Hospitals NHS Foundation Trust | Ravulizumab (prevent activation of complement component-5) + Baricitinib (acts as inhibitor of janus kinase) | Phase 4 | NCT04390464 | 1,167 SARS-CoV-2 positive hospitalized pre-ICU patients |